What Is The Best Approach To Hip Replacement For Different Patient Groups?

Published Sep 25, 2013
Calgary, AB, Canada - Advanced hip osteoarthritis (OA) is a common chronic condition causing severe joint pain and loss of joint function. Total hip arthroplasty (THA) is recognized as one of the most effective interventions to relieve pain and improve function, but with increasing life expectancy, people are now expected to outlive a primary THA, and require revision surgery. Therefore, other surgical approaches, like hip resurfacing arthroplasty (HRA), have been considered, particularly for younger, active patients. Researchers at the University of Calgary in Calgary, Canada compared the benefits and costs of HRA versus THA. A decision analytic model was constructed to estimate the expected cost-effectiveness of HRA compared to THA as measured by cost per quality-adjusted life year (QALY). The absolute differences between THA and HRA were small, with substantial uncertainty around the estimate of cost effectiveness. For younger patients (less than 50 years old) and male patients, however, HRA cost less and was associated with more QALYs. Total hip arthroplasty was a better option only in older patients (over 60 years old) and female patients. The results show that, on average, HRA was preferred above THA for younger and male patients, but THA is still a reasonable option if the patient or clinician prefers. The full study, “Cost-Utility of Metal-on-Metal Hip Resurfacing Compared to Conventional Total Hip Replacement in Young Active Patients with Osteoarthritis,” is published in Value in Health.

Value in Health (ISSN 1098-3015) publishes papers, concepts, and ideas that advance the field of pharmacoeconomics and outcomes research as well as policy papers to help health care leaders make evidence-based decisions. The journal is published bi-monthly and has over 8,000 subscribers (clinicians, decision makers, and researchers worldwide).

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a nonprofit, international, educational and scientific organization that strives to increase the efficiency, effectiveness, and fairness of health care resource use to improve health.

For more information: www.ispor.org

Related Stories

Rethinking Medication Adherence: A Stakeholder Blueprint

May 12, 2025

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a report from its Medication Adherence and Persistence Special Interest Group that provides valuable insights into the perspectives of key stakeholders on interventions to improve medication adherence. The report, “Stakeholders’ Perspectives on Medication Adherence Enhancing Interventions: An ISPOR Report,” was published in the May 2025 issue of Value in Health.

New Research Reveals Surprising Trends in Women's Health Economics Authorship

May 12, 2025

Value in Health, the official journal of ISPOR announced the publication of new research analyzing women's representation in authorship of papers submitted to and published in Value in Health. The report, “How Well Are Women Represented in Authorship in HEOR? An Analysis of Value in Health: An ISPOR Report,” was published in the May 2025 issue of Value in Health.

Redefining Value in Care for Alzheimer's Disease and Dementia

Apr 8, 2025

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced the publication of a special themed section of research papers that provide crucial insights into the complex health economics of Alzheimer's disease and related dementias (ADRD), offering a roadmap for future research and policy as the aging population grows and novel treatments emerge.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×